带领研究团队进行中晚期非小细胞肺癌液态活检研究及大数据分析、个体化精准分析；致力于非小细胞肺癌靶向治疗耐药研究多年，发表相关SGI及申报发明专利；
Our research team focus on liquid biopsy of advanced NSCLC and personality precise therapy. We have been done more years in the field of targeted drug resistance and have published a few meaningful papers and invention patents.
（一）发表论文（通讯作者🟨、第一作者）：
1😵💫、Exosomal long non-coding RNA MSTRG.292666.16 is associated with osimertinib (AZD9291) resistance in non-small cell lung cancer. Aging (Albany NY). 2020, 12(9):8001-8015；
2、 Cyclooxygenase-2 mediates gefitinib resistance in non-small cell lung cancer through the EGFR/PI3K/AKT axis. Journal of Cancer, 2020；
3🌧🗑、 Detection of plasma EGFR mutations for personalized treatment of lung cancer patients without pathologic diagnosis. Cancer Medcine, 2020；
4🚆、 Predictive value of unmethylated RASSF1A on disease progression in non-small cell lung cancer patients receiving pemetrexed-based chemotherapy. Cancer Biomarkers, 2020；
5、 A novel virtual barcode strategy for accurate panel-wide variant calling in circulating tumor DNA. BMC Bioinformatics, 2020；
6👧🏻🧍♀️、 Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients. Heliyon, 2018；
7◼️、 Engineering docetaxel-loaded micelles for nonsmall cell lung cancer: a comparative study of microfluidic and bulk nanoparticle preparation. RSC Advances, 2018𓀒；
8、 SPOP promotes SIRT2 degradation and suppresses non-small cell lung cancer cell growth. Biochem Biophys Res Commun，2017👨🏿🚒；
9、Cancer-related triplets of mRNA-lncRNA-miRNA revealed by integrative network in uterine corpus endometrial carcinoma. BioMed Research International, 2017.
（二）科研课题：
1、张江高科技园区重点项目子课题（在研，第一负责人）🧓🏽🌉；项目名称：建立NGS技术检测外周血cfDNA的检测平台（2016-08）；研究经费🫄：800万☺️；研究时间：2016年8月至2020年12月；
2、中央高校基本科研业务费专项资金资助（已结题，第一负责人）🪒；项目名称：c-KIT/PDGFα-EMT-肿瘤亚克隆演化在非小细胞肺癌EGFR-TKIs获得性耐药中作用及分子机制探讨（22120180369）；研究经费🌜：5万🚶🏻；研究时间👴🏻：2018年9月至2019年8月😴；
3📒、国基金青年项目（已结题🧗🏻♀️，第一负责人）📠；项目名称：国基金青年项目（已结题，第一负责人）；项目名称：分化抑制因子ID1在非小细胞肺癌EGFR-TKIs耐药中的作用和机制研究”（项目批准号⛹️：81301994）研究经费：23万；研究时间🍄🟫♞：2014年1月至2016年12月。
（三）专利🧑🏿🔬：
1🤲🏻、获得软件著作权1项🧺：上海市肺科医院病历随访系统V1.0（2016年10月29日），2017SR419017🧑🏽⚖️；
2、获得实用新型专利：穿刺固定器（2018年1月26日）🤹🏽♂️；ZL201621310554.2；
3、发明专利3项（公布阶段）🐉：
（1）一种人表皮生长因子酪氨酸激酶抑制剂获得性耐药肺癌细胞系及其建立方法；2018107760600🧍🏻♀️；第一发明人👮🏻♀️。
（2）一种基于微流控技术控制纳米颗粒质量参数的方法；2016103921341；第一发明人🧑🏻🎨。
（3）一种用于医学辅助教学的疾病知识管理系统及操作方法🧑🧒；201610015215X💽；第三发明人👦🏽。
（四）举办会议：
2019年12月，承办全国肺癌个体化精准治疗新进展研讨会（I类继续教育学分10分，项目编号🧒🏿：2019-03-02-006，沪）
Devoted to the research on drug resistance in targeted therapy for lung cancer, published a number of papers included in SCI, obtained the patent for invention; my team also did some basic research on liquid biopsy for advanced lung cancer and carried out big data analysis in related fields.
1.Published Articles
(1) Exosomal long non-coding RNA MSTRG.292666.16 is associated with osimertinib (AZD9291) resistance in non-small cell lung cancer. Aging (Albany NY). 2020, 12(9):8001-8015；
(2) Cyclooxygenase-2 mediates gefitinib resistance in non-small cell lung cancer through the EGFR/PI3K/AKT axis. Journal of Cancer, 2020；
(3) Detection of plasma EGFR mutations for personalized treatment of lung cancer patients without pathologic diagnosis. Cancer Medcine, 2020🪐；
(4) Predictive value of unmethylated RASSF1A on disease progression in non-small cell lung cancer patients receiving pemetrexed-based chemotherapy. Cancer Biomarkers, 2020；
(5) A novel virtual barcode strategy for accurate panel-wide variant calling in circulating tumor DNA. BMC Bioinformatics, 2020；
(6) Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients. Heliyon, 2018；
(7) Engineering docetaxel-loaded micelles for nonsmall cell lung cancer: a comparative study of microfluidic and bulk nanoparticle preparation. RSC Advances, 2018；
(8) SPOP promotes SIRT2 degradation and suppresses non-small cell lung cancer cell growth. Biochem Biophys Res Commun，2017；
(9) Cancer-related triplets of mRNA-lncRNA-miRNA revealed by integrative network in uterine corpus endometrial carcinoma. BioMed Research International, 2017. 2.
Research project：
(1)Sub-Project of Foundation in Zhangjiang High-tech Park (In progress, the chief person in charge): Establishment of a platform for detecting cfDNA in peripheral blood by NGS. Funds: 8million; Time: 2016/8-2020/12🧏🏽♂️；
(2)Fundamental Research Funds for the Central Universities (completed, the chief person in charge): Role and mechanism of c-KIT/PDGF alpha-EMT Tumor Subclone Evolution in Acquired Resistance to EGFR-TKIs in Non-small Cell Lung Cancer(Approval Number: 22120180369); Funds: 50 thousand; Time: 2018/9-2019/8🪡；
(3)National Natural Science Foundation Youth Project (completed, the chief person in charge): Role and mechanism of differentiation inhibitor ID1 in EGFR-TKIs resistance in non-small cell lung cancer (Approval Number: 81301994). Funds: 230 thousand; Time: 2014/1-2016/12. 3.
Patents:
(1)Software copyright:Medical Record Follow-up System of Shanghai Pulmonary Hospital V1.0(2016/10/29) 2017SR419017；
(2)Utility model patent: Pulmonary puncture fixator (2018/1/26) ZL201621310554.2；
(3) Invention patents (Announcement):
①Establishment of a human lung cancer cell line with acquired resistant to epidermal growth factor tyrosine kinase inhibitor; 2018107760600; First inventor.
②A Method of Controlling the Quality Parameters of Nanoparticles Based on Microfluidic Technology; 2016103921341; First inventor.
③A Kind of Disease Knowledge Management System and Its Operating Method for Medical Assistant Teaching; 201610015215X; Third Inventor.
4.Academic Conferences🐙：In December 2019, we undertook the national seminars on advances in individualized precision treatment of lung cancer (Class I continuing education credit 10, No: 2019-03-02-006, Shanghai).
